Summary:
10 therapeutic agents are in active clinical trials. Another 15 therapeutic agents are in planning stages. Currently the three (3) most likely drugs to be safe and effective are, for critically ill COVID-19 patients: (1) Remdesivir anti-viral drug by Gilead, and (2) Actemra/RoActemra (Tocilizumab) immunosuppressive drug by Roche, and for early stage SARS-CoV-2 infection: (3) Avigan (favipiravir) anti-viral drug by Fujifilm, Japan.
Published for educational purposes and social benefit, not for profit. Not a recommendation or endorsement. Always consult your doctor for medical advice.
BBC NEWS | Coronavirus: Protein [Interferon beta] treatment trial ‘a breakthrough’
The preliminary results of a clinical trial suggest a new treatment for Covid-19 dramatically reduces the number of patients needing intensive care, according to the UK company that developed it. [...]